ATE501253T1 - Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1 - Google Patents
Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1Info
- Publication number
- ATE501253T1 ATE501253T1 AT04822466T AT04822466T ATE501253T1 AT E501253 T1 ATE501253 T1 AT E501253T1 AT 04822466 T AT04822466 T AT 04822466T AT 04822466 T AT04822466 T AT 04822466T AT E501253 T1 ATE501253 T1 AT E501253T1
- Authority
- AT
- Austria
- Prior art keywords
- modulation
- retinal pigmented
- pigmented epithelial
- epithelial permeation
- inhibiting vegfr
- Prior art date
Links
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 title abstract 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000002207 retinal effect Effects 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2004/004107 WO2006056823A1 (en) | 2004-11-26 | 2004-11-26 | Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE501253T1 true ATE501253T1 (de) | 2011-03-15 |
Family
ID=34959531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04822466T ATE501253T1 (de) | 2004-11-26 | 2004-11-26 | Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090087424A1 (de) |
| EP (1) | EP1827602B1 (de) |
| AT (1) | ATE501253T1 (de) |
| DE (1) | DE602004031786D1 (de) |
| WO (1) | WO2006056823A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
| US20070117750A1 (en) * | 2005-10-06 | 2007-05-24 | Muhammad Abdulrazik | Method for enhanced ocular drug penetration |
| KR101083247B1 (ko) | 2009-06-05 | 2011-11-14 | 중앙대학교 산학협력단 | Ｆｔｙ720을 유효성분으로 포함하는 미백용 조성물 |
| RU2703145C2 (ru) * | 2014-02-06 | 2019-10-15 | Джензим Корпорейшн | Композиции и способы лечения и предотвращения дегенерации желтого пятна |
| KR20250051157A (ko) | 2019-06-05 | 2025-04-16 | 리제너론 파아마슈티컬스, 인크. | 정밀 투여량 전달을 위한 디바이스 및 방법 |
| US12226452B2 (en) * | 2020-03-04 | 2025-02-18 | The Schepens Eye Research Institute, Inc. | Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710174B2 (en) * | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
| US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US5916763A (en) * | 1995-11-09 | 1999-06-29 | The Regents Of The University Of California | Promoter for VEGF receptor |
| AU738806B2 (en) * | 1996-09-24 | 2001-09-27 | Merck & Co., Inc. | Gene therapy for inhibition of angiogenesis |
| ATE331806T1 (de) * | 1996-11-21 | 2006-07-15 | Kyowa Hakko Kogyo Kk | Gegen humanen vegf-rezeptor flt-1 gerichteter, monoklonaler antikörper. |
| US6630973B1 (en) * | 1999-03-31 | 2003-10-07 | Fuji Photo Film Co., Ltd. | Optically anisotropic cellulose ester film containing discotic compound |
| CN1209638C (zh) * | 2000-05-15 | 2005-07-06 | 富士胶片株式会社 | 光学补偿片、偏振板和液晶显示器 |
| US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20030016325A1 (en) * | 2001-07-23 | 2003-01-23 | Nec Corporation | Liquid crystal display device |
| WO2003012105A2 (en) * | 2001-08-01 | 2003-02-13 | University Of Bristol | Vegf isoform |
| US20040062751A1 (en) * | 2002-01-17 | 2004-04-01 | Genetix Pharmaceuticals, Inc. | Methods for inhibiting angiogenesis |
| JP2003307621A (ja) * | 2002-04-18 | 2003-10-31 | Nitto Denko Corp | 粘着型光学フィルムおよび画像表示装置 |
| US20030207941A1 (en) * | 2002-05-03 | 2003-11-06 | Bingaman David P. | Method of treating vascular endothelial growth factor mediated vascular disorders |
| JP4054670B2 (ja) * | 2002-12-13 | 2008-02-27 | 富士フイルム株式会社 | 偏光板および液晶表示装置 |
| JP4301544B2 (ja) * | 2003-01-07 | 2009-07-22 | 日東電工株式会社 | 画像表示装置の製造方法、画像表示装置および粘着型光学フィルム |
| WO2005000223A2 (en) * | 2003-06-04 | 2005-01-06 | Children's Medical Center Corporation | Method of treating retinopathies and disorders associated with blood vessel loss |
-
2004
- 2004-11-26 US US11/791,759 patent/US20090087424A1/en not_active Abandoned
- 2004-11-26 DE DE602004031786T patent/DE602004031786D1/de not_active Expired - Lifetime
- 2004-11-26 WO PCT/IB2004/004107 patent/WO2006056823A1/en not_active Ceased
- 2004-11-26 AT AT04822466T patent/ATE501253T1/de not_active IP Right Cessation
- 2004-11-26 EP EP04822466A patent/EP1827602B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006056823A1 (en) | 2006-06-01 |
| WO2006056823A8 (en) | 2006-08-24 |
| DE602004031786D1 (de) | 2011-04-21 |
| US20090087424A1 (en) | 2009-04-02 |
| EP1827602B1 (de) | 2011-03-09 |
| EP1827602A1 (de) | 2007-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066877A (es) | Moduladores canabinoides de tetrahidro-indazol | |
| EA200870396A1 (ru) | Лечение аллергических заболеваний глаз | |
| WO2008021210A3 (en) | Methods and compositions for the treatment of neurodegenerative disorders | |
| EP1732484A4 (de) | Ophthalmisches implantat zur behandlung von glaukom | |
| ECSP099414A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa | |
| EA200700333A1 (ru) | Терапевтические применения ингибиторов rtp801 | |
| EA201300272A1 (ru) | Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
| CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
| ATE502633T1 (de) | Cyclosporins zur behandlung und vorbeugung von augenerkrankungen | |
| TW200505829A (en) | Protease inhibitors for coronaviruses and sars-cov and the use thereof | |
| WO2005072308A3 (en) | Cgrp receptor antagonists | |
| WO2019051327A3 (en) | BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS | |
| BRPI0512500A (pt) | tratamento ou condições envolvendo desmielinação | |
| DE602006010834D1 (de) | Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| EP1254662A3 (de) | Methode und Kits zur Depressionsbehandlung oder Vorbeugung der Verschlechterung kognitiver Funktionen | |
| ATE399557T1 (de) | Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen | |
| ATE501253T1 (de) | Modulierung der retinalen pigmentierten epithel- permeation durch hemmung von vegfr-1 | |
| ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
| WO2010077976A3 (en) | Prokineticin receptor antagonists and uses thereof | |
| ATE451361T1 (de) | Materialien und methoden zur behandlung von koagulationsstörungen | |
| NO20065768L (no) | Karbonsamid-opioidforbindelser | |
| WO2007127711A3 (en) | Abnormal cannabidiols as agents for lowering intraocular pressure | |
| ATE412636T1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| EA200701181A1 (ru) | Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |